

CiMUS Open Innovation Day

“Public Private Partnership (PPP) in early drug discovery”

February 18th 2015

Venue: CiMUS Research Center (Santiago de Compostela)

(Limited seats available)

February 18th, Wednesday

	Opening and Innopharma introduction
09:00-09:30	Innopharma introduction- Ángel Carracedo and Mabel Loza- <i>Innopharma coordinators (USC)</i>
09:30-10:50	Open PHACTS session: Building the Open Pharmacological Space
	Open PHACTS Project
09:30-09:50	Stefan Senger - <i>EFPIA coordinator of the IMI Open PHACTS Project</i>
	Novel Approaches for Pan Kinase Profiling and Drug Discovery
09:50-10:10	Edgar Jacoby - <i>Senior Principal Scientist Molecular Informatics at J&J</i>
	Open PHACTS Foundation
10:10-10:30	Bryn Williams-Jones - <i>CEO of the Open PHACTS Foundation.</i>
10:30-10:50	Joint discussion
10:50-11:20	Coffee break
11:20-12:15	The Lilly Open Innovation Drug Discovery (OIDD) Program. Marta Piñeiro- <i>Director, Open Innovation Drug Discovery, Eli -Lilly and Company</i> María Jesús Blanco- <i>Director, Discovery Chemistry Research & Technologies Eli-Lilly and Company</i>
12:15-13:15	Lunch

Innopharma: An initiative from Galicia for early drug discovery

Innopharma is a drug discovery Galician (Spain) initiative that combines Genomics and Drug Screening Platforms, led by Dr Ángel Carracedo and Dr Mabel Loza. It is located at CIMUS (Center for Research in Molecular Medicine and Chronic Diseases) of the University of Santiago de Compostela and is financed by the EU Technology Fund, via the Spanish Ministry of Economy and Competitiveness.

Innopharma aims to potentiate the pharmacogenomics early drug discovery from Galicia, by filling the gap between the basic research on new therapeutic mechanisms and its industrial application.

Open PHACTS: Building the Open Pharmacological Space

Currently, pharmaceutical companies expend significant and duplicated efforts aligning and integrating internal information with public data sources. This process is difficult and inefficient and the vast majority of drug discovery sources cannot easily interoperate.

To reduce the barriers to drug discovery in industry, academia and for small businesses, the Open PHACTS IMI project has developed the Open PHACTS Discovery Platform - providing access to a collection of tools and services to question multiple integrated and publicly available data sources to support drug discovery.

USC, as a partner of this consortia and host of the Second Open PHACTS Workshop, organizes this session following its aim of developing efficient methodology in the frame of drug discovery. It also fits its initiative in promoting the Public Private Partnership (PPP) as a strategy of collaboration.

The Lilly Open Innovation Drug Discovery (OIDD) Program: Connecting Compounds to Patients

The Lilly Open Innovation Drug Discovery (OIDD) program was launched in August 2011 to engage investigators worldwide in the identification of novel compounds that have potential to be developed into drug candidates for key areas of disease of interest to Lilly. OIDD has been embraced by the scientific community, both scientists and technology transfers professionals alike. To date, more than 350 academic institutions and small biotech companies around the globe have become affiliated with the program and thousands of compound samples have been evaluated in both phenotypic and target-based screening modules. In addition, the OIDD panel includes a neglected disease screening module (Tuberculosis)

The presentation will describe the scientific foundation behind OIDD, the business model and some recent examples of completed and ongoing collaboration.

USC presents the Eli-Lilly OIDD program to the Galician and Spanish scientific community and opens a new understanding of developing new models of collaboration in Drug Discovery.

For further information, please contact to: Begoña Roibás (begona.roibas@usc.es)